Condition: Intrahepatic Cholangiocarcinoma (ICC) · Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
This is a single-arm, open-label, multi-center phase 2 clinical trial of ICP-192. The purpose of this study is to evaluate the efficacy and safety in patients with FGFR2-Rearranged unresectable or metastatic intrahepatic cholangiocarcinoma who failed prior therapy
This description comes directly from the study's public registry record.
Jin Li · 021-38804518 · lijin@csco.org.cn
Always discuss trial participation with your own doctor first.
| Anhui Provincial Hospital | Hefei, Anhui, China | Not Yet Recruiting |
| Cancer Hospital, Chinese Academy of Medical Sciences | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Peking Union Medical College Hospital | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Beijing Youan Hosptital,Capital Medical University | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Beijing Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Fujian Cancer Hospital | Fujian, Fujian, China | Not Yet Recruiting |
| Fujian Medical University Union Hospital | Fuzhou, Fujian, China | Not Yet Recruiting |
| Mengchao hepatobiliary Hospital of FuJian Medical university | Fuzhou, Fujian, China | Not Yet Recruiting |
| Foshan First People's Hospital | Foshan, Guangdong, China | Not Yet Recruiting |
| Sun Yat-sen Memorial Hospital | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Not Yet Recruiting |
+ 32 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05678270